Tekmira, USAMRIID Publish Data Showing Ebola Protection in Primates Using SNALP RNAi Rx
June 03, 2010
Tekmira, USAMRIID Publish Data Showing Ebola Protection in Primates Using SNALP RNAi Rx
The data, Tekmira President and CEO Mark Murray said in a statement, "are the first demonstration that RNAi is efficacious in an otherwise lethal primate infectious disease setting," and support the utility of RNAi in infectious diseases.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Alnylam Data Shows 'Predictable Correlation' of Clinical, Preclinical Findings on Cancer Drug
December 16, 2010 / Gene Silencing News - Three RNAi, miRNA Firms Record Strong Gains in Stock Value Since the End of 2008
April 30, 2009 / Gene Silencing News - Tekmira Files IND for Hypercholesterolemia Drug with US Regulators
April 16, 2009 / Gene Silencing News - Tekmira Delays Start of Cancer Drug Trial, Sees Expanded Roche Partnership in '09
March 26, 2009 / Gene Silencing News - Strands
February 26, 2009 / Gene Silencing News